Objective: The objective of this study is to determine the relationship between inflammatory interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP)] and coagulation (D-dimer) biomarkers and the presence and type of anaemia among HIV-positive individuals.
Introduction
Anaemia is the most common haematological abnormality in HIV disease [1, 2] and is associated with increased morbidity and mortality [3] [4] [5] [6] [7] [8] . Even minor decreases in haemoglobin levels are clinically relevant: a 1 g/dl decrease in haemoglobin was found to be independently correlated with a 57% higher risk of death in those with HIV [3] .
The morphological assessment of red cell size based on mean corpuscular volume (MCV) is helpful for assessment of the cause of anaemia. Whereas microcytic (MCV < 80 fl) and macrocytic (MCV > 100 fl) anaemias are often caused by deficiencies of iron and folic acid/ cobalamin, respectively, normocytic anaemia (MCV 80-100 fl) is predominately seen in patients with chronic disease [9] . In the general population, there is mounting evidence that enhanced inflammation contributes to the development of normocytic anaemia via interleukin-6 (IL-6) dependent pathways [10] . IL-6 induces the formation of hepcidin, a hepatic hormone that interferes with iron absorption and promotes iron uptake by the reticuloendothelial system, ultimately leading to anaemia [11, 12] .
In this study, we set out to determine the relationship between inflammatory biomarkers [IL-6 and highsensitivity C-reactive protein (hsCRP)] and the presence and type of baseline anaemia among HIV-positive individuals participating in an international HIV treatment trial. Given the close link between inflammation and coagulation in HIV disease, we also determined the association between D-dimer levels and anaemia.
Materials and methods
The design and results of the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4 þ Counts under Active Antiretroviral Therapy (SILCAAT) trial have been described elsewhere [13] . Briefly, the SILCAAT trial compared IL-2 as well as combination antiretroviral therapy (cART) with cART alone in 1695 individuals with entry CD4 þ T-cell counts between 50 and 299 cells/ml. All participants with biomarker levels, haemoglobin and MCV measurements at entry were included in this study.
We defined anaemia as a haemoglobin of 14 g/dl or less in men and of 12 g/dl or less in women [3, 5, 8] . Anaemia was classified as microcytic, normocytic or macrocytic on the basis of MCV values below 80, between 80 and 100, and over 100 fl, respectively. On the basis of strong associations of IL-6, hsCRP and D-dimer with all-cause mortality [14] and the observation that these biomarkers were elevated in treated HIV-positive individuals compared with the general population [15] , IL-6, hsCRP and D-dimer were measured on stored plasma at baseline for all consenting SILCAAT participants. IL-6 and hsCRP were measured using the Chemiluminescent Sandwich immunoassay (R&D Systems, Minneapolis, Minnesota, USA) and D-dimer was measured using the VIDAS immunoassay (BioMerieux Inc., Durham, North Carolina, USA). Measurements were performed by SAIC-Frederick and lower limits of detection for IL-6, hsCRP and D-dimer were 0.156 pg/ml, 0.078 and 0.045 mg/ml, respectively.
Demographics and clinical data from participants with and without anaemia and those with normocytic and macrocytic anaemia were compared. The association between inflammatory (IL-6 and hsCRP) and coagulation (D-dimer) biomarkers and anaemia was assessed by multivariable logistic regression. IL-6, hsCRP and Ddimer levels were log 2 -transformed because their distributions were right-skewed. With this approach, a one log 2 higher level of a biomarker corresponds to a two-fold higher level of the marker. Variables adjusted for were chosen on the basis of their epidemiological importance and biological plausibility and included demographics (age, race and sex), BMI, HIV plasma RNA levels, CD4 þ T-cell counts (nadir and baseline), Karnofsky score, previous AIDS diagnosis, hepatitis B [defined as hepatitis B surface antigen (HBsAg) seropositivity by ELISA] and hepatitis C (defined as seropositivity for antihepatitis-C antibodies by enzyme immunoassay) coinfection and use of zidovudine. Log 2-transformed levels of IL-6, hsCRP and D-dimer were also entered into the logistic regression models and were thus adjusted for simultaneously.
As the best haemoglobin cut-off to define anaemia may be debatable, a multivariable linear regression model, which was adjusted for the aforementioned covariates, was deployed to further explore associations between biomarkers and haemoglobin. Continuous haemoglobin levels were modelled as the outcome. Regression coefficients with 95% confidence intervals (95% CIs) were calculated to assess the independent contribution of IL-6, hsCRP and D-dimer to the variance of haemoglobin levels.
Because macrocytic anaemia can be a manifestation of zidovudine toxicity [16, 17] , analyses were repeated excluding participants receiving zidovudine. Statistical analyses were performed using SAS (version 9.2; SAS Institute Inc., Cary, North Carolina, USA).
Results
Baseline haemoglobin, MCV and biomarker levels were available in 1410 out of 1695 individuals enrolled in SILCAAT. Among the 1410 participants in the present study, the median (interquartile range, IQR) age was 41 (36-48) years; 84.2% were men, 81.1% were white, 8.3% had hepatitis B and 25.6% had hepatitis C coinfection. Study participants received cART for a median (IQR) of 4.4 (2.0, 7.8) years. The median (IQR) baseline CD4 þ T-cell count was 202 (149-255) cells/ml. Most (81.8%) had an HIV RNA lower than 500 copies/ml plasma. A total of 285 participants lacked biomarker measurements at baseline and were excluded. Data were missing mainly among participants from Argentine, Brazilian and Belgian study sites, wherein blood samples were not routinely collected. Relative to the studied cohort, these individuals had received cART for a shorter time, were younger, were more likely be on zidovudine and less likely to be white, but had otherwise similar demographic and clinical characteristics (data not shown).
A total of 313 (22.2%) participants had anaemia. When compared with participants with normal haemoglobin levels, those with anaemia were more likely to be older, black, male and on zidovudine. They also had lower baseline CD4 þ T-cell counts and lower Karnofsky scores (Table 1) . D-dimer, hsCRP and IL-6 levels were significantly higher in those with anaemia than in those without anaemia (Table 1) .
Of the 313 anaemic patients, 13 (4.1%), 85 (27.2%) and 215 (68.7%) had microcytic, normocytic and macrocytic anaemia, respectively (supplementary Table 1 , http:// links.lww.com/QAD/A533). As expected, zidovudine use was significantly more common in participants with macrocytic anaemia than in those with normocytic anaemia (78.6 versus 14.1%, respectively; P < 0.001).
Inflammation, coagulation and anaemia in HIV disease Borges et al. 1793 Furthermore, those with macrocytic anaemia were more likely to be black, male and to be virologically suppressed than those with normocytic anaemia. The levels of IL-6, hsCRP and D-dimer did not differ significantly between participants with normocytic and macrocytic anaemia (Supplementary Table 1 , http://links.lww.com/QAD/ A533).
Considering all participants, higher levels of IL-6 and D-dimer, but not hsCRP, were found to be associated with anaemia in univariate and adjusted analyses ( Fig. 1) . Adjusted relative odds of anaemia per two-fold higher biomarker levels were 1.35 (P < 0.001) for D-dimer, 0.99 for hsCRP (P ¼ 0.86) and 1.22 (P ¼ 0.007) for IL-6. Similar associations were seen in those with normal and high MCV values (Fig. 1) . The percentage of patients with anaemia increased with higher quintiles of D-dimer and IL-6 levels (supplementary Figures 1 and 2 , http:// links.lww.com/QAD/A533). The presence of anaemia did not appear to be linearly associated with activated coagulation, as it was much higher in the top two Ddimer quintiles and similar in the bottom three quintiles (supplementary Figure 1 , http://links.lww.com/QAD/ A533).
In multivariable liner regression models, higher IL-6 and D-dimer levels were found to be independently correlated with lower haemoglobin. Adjusted regression coefficients (95% CI) were À0.13 (À0.21 to À0.06), P < 0.001, for IL-6 (i.e. haemoglobin levels were 0.13 g/dl lower on average per two-fold higher IL-6 level) and À0.25 (À0.34 to À0.16), P < 0.001, for D-dimer. No significant association was observed between hsCRP and haemoglobin [regression coefficient (95%CI) 0.00 (À0.04 to 0.04), P ¼ 0.98] in adjusted analyses.
Analyses excluding individuals using zidovudine rendered consistent results (data not shown).
Discussion
In the largest study to date investigating the relationship among inflammation, coagulation and anaemia in the setting of antiretroviral-treated HIV infection, we found that, among antiretroviral-treated adults with moderate CD4 þ T cells counts, higher levels of both IL-6 and D-dimer are associated with the presence of anaemia after adjustment for demographic and clinical variables. The risk for anaemia appeared to increase most dramatically in those with the highest levels of IL-6 and D-dimer. This association was not restricted to normocytic anaemia, as we initially hypothesized, but was consistently seen across all MCV levels, although it is possible that zidovudine, which was used by the majority of participants with macrocytosis (supplementary Table 1 , http://links.lww. com/QAD/A533), could have caused macrocytic anaemia in patients who otherwise would have had normocytic anaemia.
The pathogenesis of anaemia in HIV infection is complex and multifactorial. Possible causes include blood loss (i.e. neoplastic disease or gastrointestinal opportunistic infection), bone marrow infiltration or suppression, drugrelated or infection-related haemolysis, nutritional deficiencies (iron, folic acid or cobalamin), hypogonadism and myelo-suppressive drugs [18] . It is clear that anaemia is associated with decreased survival in several other chronic conditions [19, 20] . With HIV infection, however, questions remain as to whether anaemia is an epiphenomenon as a consequence of the underlying severe disease or is causally related to morbidity and mortality. Our findings suggest that the previously identified link between anaemia and increased morbidity and mortality in HIV-positive individuals may reflect in part elevated inflammation and coagulation.
Our data are broadly consistent with the results of the Veterans Aging Cohort Study, which also found higher D-dimer and IL-6 levels in those with lower haemoglobin values [21] , although in that study, the correlation between haemoglobin and biomarkers was not adjusted for confounding. Furthermore, an earlier study found an association between increasing haemoglobin levels after cART initiation and decreased plasma levels of the inflammatory biomarkers neopterin and tumour necrosis factor-alpha (TNF-a) [22] . Finally, structured cART interruptions resulted in increased levels of inflammatory and coagulation markers [14] and an increased risk of new and worsening anaemia [8] . In multivariable models adjusted for all three biomarkers simultaneously, we did not find significant associations between hsCRP and anaemia or between hsCRP and haemoglobin levels. Adjustment for a higher number of variables and for other biomarkers had already been shown to significantly reduce associations between hsCRP and clinical outcomes [23] . Among other factors, this may be due to the fact that the hepatic production of hsCRP is determined by IL-6 [24] .
Several issues need to be considered when interpreting our results. First, because this is a cross-sectional study, we could not establish temporal relationship, and no definitive inference of causality between enhanced inflammation/coagulation and anaemia can be made. Second, we could not adjust for environmental factors or for socio-economic status. Third, we have not explored specific causes of anaemia, and information on reticulocyte counts, ferritin, folic acid, cobalamin and hepcidin levels was not routinely collected. Fourth, the number of participants with microcytic anaemia was too small to perform statistical analyses. Fifth, we had no data on hepatitis C virus (HCV) RNA and hepatitis B virus (HBV) DNA plasma levels. As participants with detectable or higher HCV-RNA/HBV-DNA may have had more active hepatic disease, examining differences between them and coinfected participants with undetectable HCV-RNA/HBV-DNA would have been helpful. Finally, SILCAAT recruited participants who did not achieve immunological reconstitution despite cART use for several years. As the bone marrow from immunological nonresponders have impaired clonogenic capability and altered cytokine production [25] , which might have contributed to the development of anaemia, confirmation of our findings by studies involving cART-treated participants with high CD4 þ T-cells counts is warranted. As the occurrence of prior AIDS-defining events was comparable in those with and without anaemia, we do not believe that our findings can be explained by concurrent opportunistic infections resulting in anaemia and raised levels of inflammatory and coagulation biomarkers.
In conclusion, we have shown that higher levels of IL-6 and D-dimer are associated with anaemia in HIV-treated adults. These associations remained strong after adjustment for clinical and demographic covariates and are seen across all MCV levels, a finding that suggests that activation of coagulation and inflammation may contribute to the development of all types of anaemia in HIV-infected individuals. Lower haemoglobin levels may provide indirect evidence of activation of coagulation/ inflammation among HIV-infected adults. Further studies are needed to explore whether the established link between anaemia and increased morbidity and mortality has a causal component related to enhanced inflammation and coagulation.
